Members Login
ACTG Network
  • Home
  • About
    • About the ACTG
    • Leadership and Organizational Matrix
    • ACTG Committees and Centers
    • Underrepresented Populations
    • Contact the LOC
  • Clinical Trials
    • About the Clinical Trials Process
    • Active Clinical Trials
    • Clinical Trials Resources
    • Study Result Slides
  • Sites
  • Community
    • Global Community Advisory Board
    • Community Resources
    • They Became My Family
  • Publications
  • News
    • In Memorium
    • Press Releases & Announcements
    • Newsletters
  • For Researchers
    • Submit a Proposal
    • Small Clinical Trials RFA –HIV Remission & Cure
    • Specimen Repository Website
    • HIV Databases
  • Rise Above COVID

Study Results

  • REPRIEVE TRIAL Cardiovascular Disease Risk and Prevention in Inflammation: The REPRIEVE Trial in HIV

    January 11, 2023 Alexis Sexton Study Results

    To see study results from the REPRIEVE trial click here.

    Read more
  • A5360 (MINMON): A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavirin-free HCV Therapy to Populations Living with HCV Who Are HCV Treatment Naïve with Evidence of Active HCV Infection

    October 20, 2021 Alexis Sexton Study Results

    To see study results from A5360 click here.

    Read more
  • A5305: Phase II Study of Maraviroc (MVC)-Containing Regimens for HIV PrEPin MSM, Transgender Women and Cisgender Women

    October 20, 2021 Alexis Sexton Study Results

    To see study results from A5305 click here.

    Read more
  • A5349: Rifapentine-containing Treatment Shortening Regimens for Pulmonary Tuberculosis

    October 20, 2021 Alexis Sexton Study Results

    To see study results from A5349 click here.

    Read more
  • A5336: A Randomized, Pilot Study of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults

    October 20, 2021 Alexis Sexton Study Results

    To see study results from A5336 click here.

    Read more
  • A5333s: Mechanistic Sub-study of A5332: Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)

    October 20, 2021 Alexis Sexton Study Results

    To see results of A5333s click here.

    Read more

Mission

The mission of the ACTG Network
is to cure HIV and reduce the
burden of disease due to HIV
and its complications, including
tuberculosis and viral hepatitis.

Useful Links

Government Resources
Clinical Trials Resources
Grants and Contracts
New Members

© ACTG. All Rights Reserved. | admin login